Olympic legend Shannon Miller reflects on her 15-year ovarian cancer journey and why oncology nurses are the key to breaking ...
In addition to the drugs themselves, the UCI study identified specific patient-related factors that increased the likelihood ...
TROPION-Breast02 data show datopotamab deruxtecan extends stability and delays the need for new treatment lines in first-line ...
Results from the Phase 3 RASolute 302 study presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting ...
During an interview at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo Tarantino, MD, of the Dana ...
Adding ipatasertib to pembrolizumab improved ORR to 41% in first-line R/M HNSCC, significantly outperforming pembrolizumab ...
For more than two decades, transarterial chemoembolization (TACE) has served as the global standard of care for patients with ...
At ASCO 2026, experts discussed balancing the survival benefits of GLP-1 RAs with the nursing challenge of managing cancer-related anorexia. The rapid integration of GLP-1 receptor agonists (GLP-1 RAs ...
The FDA approved Cavhanza, a nilotinib ODT that allows co-administration with PPIs and H2RAs, easing dosing and administration for Ph+ CML patients. The U.S. Food and Drug Administration (FDA) has ...
Final KEYNOTE-522 analysis shows 85.1% 7-year OS in early TNBC. Dr. Javier Cortes details nursing management of immune-related side effects. At the 2026 American Society of Clinical Oncology (ASCO) ...
ASCO 2026 data show GLP-1 RAs reduce HR+/HER2- breast cancer risk and improve overall survival in non-diabetic women with a BMI of 25-35 kg/m². Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results